Molecular and Cellular Pathobiology The Metabolomic Signature of Malignant Glioma Re fl ects Accelerated Anabolic Metabolism

Although considerable progress has been made toward understanding glioblastoma biology through large-scale genetic and protein expression analyses, little is known about the underlying metabolic alterations promoting their aggressive phenotype. We conducted global metabolomic profiling on patient-derived glioma specimens and identified specific metabolic programs differentiating low- and high-grade tumors, with the metabolic signature of glioblastoma reflecting accelerated anabolic metabolism. When coupled with transcriptional profiles, we identified the metabolic phenotype of the mesenchymal subtype to consist of accumulation of the glycolytic intermediate phosphoenolpyruvate and decreased pyruvate kinase activity. Unbiased hierarchical clustering of metabolomic profiles identified three subclasses, which we term energetic, anabolic, and phospholipid catabolism with prognostic relevance. These studies represent the first global metabolomic profiling of glioma, offering a previously undescribed window into their metabolic heterogeneity, and provide the requisite framework for strategies designed to target metabolism in this rapidly fatal malignancy.

[1]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.

[2]  S. Eckhardt,et al.  Clinical Applications of Metabolomics in Oncology: A Review , 2009, Clinical Cancer Research.

[3]  K. Aldape,et al.  Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation , 2011, Nature.

[4]  Jing Chen,et al.  Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth , 2009, Science Signaling.

[5]  H. Christofk,et al.  Pyruvate kinase M2 is a phosphotyrosine-binding protein , 2008, Nature.

[6]  R. Kauppinen,et al.  Choline‐Containing Compounds in Human Astrocytomas Studied by 1H NMR Spectroscopy In Vivo and In Vitro , 1994, Journal of neurochemistry.

[7]  J. Uhm,et al.  The transcriptional network for mesenchymal transformation of brain tumours , 2010 .

[8]  J. Kurhanewicz,et al.  Correlation of phospholipid metabolites with prostate cancer pathologic grade, proliferative status and surgical stage – impact of tissue environment , 2011, NMR in biomedicine.

[9]  P. Tofilon,et al.  Activation of the unfolded protein response contributes toward the antitumor activity of vorinostat. , 2010, Neoplasia.

[10]  D. Hwang,et al.  Prediction of Pathology and Survival by FDG PET in Gliomas , 2003, Journal of Neuro-Oncology.

[11]  C. Dang PKM2 Tyrosine Phosphorylation and Glutamine Metabolism Signal a Different View of the Warburg Effect , 2009, Science Signaling.

[12]  R. Gillies,et al.  Characterization of breast cancers and therapy response by MRS and quantitative gene expression profiling in the choline pathway , 2009, NMR in biomedicine.

[13]  Jason W. Locasale,et al.  Inhibition of Pyruvate Kinase M2 by Reactive Oxygen Species Contributes to Cellular Antioxidant Responses , 2011, Science.

[14]  Santosh Kesari,et al.  Malignant gliomas in adults. , 2008, The New England journal of medicine.

[15]  R. Deberardinis Serine metabolism: some tumors take the road less traveled. , 2011, Cell metabolism.

[16]  J. Mackey,et al.  Metabolic Modulation of Glioblastoma with Dichloroacetate , 2010, Science Translational Medicine.

[17]  Mark Noble,et al.  Characteristic metabolic profiles revealed by 1H NMR spectroscopy for three types of human brain and nervous system tumours , 1995, NMR in biomedicine.

[18]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[19]  Andy Liaw,et al.  Classification and Regression by randomForest , 2007 .

[20]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[21]  Gregory Stephanopoulos,et al.  Amplification of phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis , 2012, BMC Proceedings.

[22]  M. V. Heiden,et al.  Targeting cancer metabolism: a therapeutic window opens , 2011, Nature Reviews Drug Discovery.

[23]  Corey D. DeHaven,et al.  Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. , 2009, Analytical chemistry.

[24]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[26]  Z. Bhujwalla,et al.  Molecular Causes of the Aberrant Choline Phospholipid Metabolism in Breast Cancer , 2004, Cancer Research.

[27]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[28]  이연수 Functional genomics reveal that the serine synthesis pathway is essential in breast cancer , 2011 .

[29]  Julian L. Griffin,et al.  Metabolic profiles of cancer cells , 2004, Nature Reviews Cancer.

[30]  R. Deberardinis,et al.  Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis , 2007, Proceedings of the National Academy of Sciences.

[31]  O. Warburg über den Stoffwechsel der Carcinomzelle , 1925, Klinische Wochenschrift.

[32]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[33]  S. Canevari,et al.  Alterations of choline phospholipid metabolism in ovarian tumor progression. , 2005, Cancer research.

[34]  O. Warburg,et al.  THE METABOLISM OF TUMORS IN THE BODY , 1927, The Journal of general physiology.

[35]  E. T. Gawlinski,et al.  Acid-mediated tumor invasion: a multidisciplinary study. , 2006, Cancer research.

[36]  C. Boschek,et al.  Pyruvate kinase type M2 and its role in tumor growth and spreading. , 2005, Seminars in cancer biology.

[37]  F. Ducray,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[38]  John D. Storey,et al.  Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Anne M. Evans,et al.  Organization of GC/MS and LC/MS metabolomics data into chemical libraries , 2010, J. Cheminformatics.

[40]  Lining Guo,et al.  Untargeted Metabolomic Profiling as an Evaluative Tool of Fenofibrate-Induced Toxicology in Fischer 344 Male Rats , 2009, Toxicologic pathology.

[41]  Ralph J Deberardinis,et al.  Brick by brick: metabolism and tumor cell growth. , 2008, Current opinion in genetics & development.

[42]  Ru Wei,et al.  The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth , 2008, Nature.

[43]  Leo Breiman,et al.  Random Forests , 2001, Machine Learning.

[44]  K. Kinzler,et al.  Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome , 2011, Proceedings of the National Academy of Sciences.

[45]  F. Podo Tumour phospholipid metabolism , 1999, NMR in biomedicine.